[F-18]FBR
Neurocysticercosis
National Institute of Mental Health (NIMH)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Neurocysticercosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Albendazole R-Evolution Worldwide S.r.l. Impresa Sociale | Phase 4 | BBB |
Praziquantel R-Evolution Worldwide S.r.l. Impresa Sociale | Phase 4 | BBB |
PBR28 National Institute of Mental Health (NIMH) | Phase 1 | CC |
DEXAMETHASONE Johns Hopkins University | N/A | D |
PHENYTOIN Johns Hopkins University | N/A | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →